EURECA EURopean Epitranscriptomics of Cancer Academy
- Coordinator
- Erasmus Universitair Medisch Centrum Rotterdam, Netherlands
- Runs
- 1 November 2025 to 31 October 2029
- Status
- Running
- EU funding
- €4.2m
- Total cost
- —
- Partners
- 19 organisations in 8 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101226733
What the project is doing
In the project's own words, from its summary on CORDIS.
The overarching objective of EURECA - The European Epitranscriptomics of Cancer Academy, is to train young doctoral candidatesinto excellence at the frontiers of basic and translational research by exploiting the cancer epitranscriptome to answer unmet clinicalneeds in cancer diagnosis, prognosis, and therapeutics and to drive change through knowledge and research. Epitranscriptomics is a new science field that studies RNA modifications (epitranscriptomic marks) and their function in regulation ofgene expression.
It is long known that many different RNA modifications exist. Yet, the true dimensions of the epitranscriptome wereunveiled only in the last decade. It is now evident that RNA modifications affect the stability, function, subcellular localization andeven immunogenicity of RNA to modulate essential cell programs like cell proliferation, differentiation, and stress response. Pathological changes in the epitranscriptome are seen as a new cancer hallmark: an independent mode of genetic reprogrammingshaping cancer’s cell fate.
We thus foresee that the epitranscriptome will prove to be a fundamental layer of gene regulationamenable to the clinics as a valuable tool in cancer diagnosis, prognosis and therapy. Focusing on RNA methylation and RNA editing in three different cancers, EURECA’s doctoral candidates will investigate thecommonalities and differences in the epitranscriptomic landscape and underlying mechanisms, while searching for novel biomarkersand treatment strategies to combat cancer and while expanding the epitranscriptomics toolbox.
The candidates will join a purposelyestablished European network of outstanding academic groups and innovative biotech companies devoted to advancing thefundamental knowledge of RNA modifications and its translation to innovative solutions for patient care. The EURECA DoctoralNetwork is the first European effort to challenge the uncharted territory of the epitranscriptome for the benefit of cancer patients.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Coordinator |
| Lexogen GmbH | Wien | Austria | Associatedpartner |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| Open Science - Lebenswissenschaften Im Dialog | Wien | Austria | Associatedpartner |
| Universite Libre De Bruxelles | Bruxelles | Belgium | Participant |
| Johannes Gutenberg-Universitat Mainz | Mainz | Germany | Participant |
| Flomics Biotech SL | Barcelona | Spain | Participant |
| Fundacio Centre De Regulacio Genomica | Barcelona | Spain | Participant |
| Universidad Pompeu Fabra | Barcelona | Spain | Associatedpartner |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Universite De Lorraine | Nancy Cedex | France | Participant |
| Universite De Montpellier | Montpellier | France | Associatedpartner |
| Universite Lyon 1 Claude Bernard | Villeurbanne Cedex | France | Participant |
| Universita Degli Studi Di Bari Aldo Moro | Bari | Italy | Participant |
| Universita Degli Studi Di Trento | Trento | Italy | Participant |
| Stichting European Urological Foundation | Arnhem | Netherlands | Associatedpartner |
| Instituto Portugues De Oncologia Do Porto Francisco Gentil, Epe | Porto | Portugal | Participant |
| Universidade Do Porto | Porto | Portugal | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS